| Literature DB >> 35557516 |
Peng Teng1, Xiaoyi Dai2, Yu Zou1, Shuai Yuan3, Yan Chen3, Liang Ma1, Yiming Ni1.
Abstract
Background: This study aimed to investigate the course of tricuspid annulus dilation in functional tricuspid regurgitation with varied severities by direct intraoperative assessment.Entities:
Keywords: functional tricuspid regurgitation; tricuspid annular dilation; tricuspid annulus (TA); tricuspid repair; tricuspid valve annuloplasty
Year: 2022 PMID: 35557516 PMCID: PMC9086675 DOI: 10.3389/fcvm.2022.889163
Source DB: PubMed Journal: Front Cardiovasc Med ISSN: 2297-055X
Preoperative and operative data.
|
|
|
|
|
| |
|---|---|---|---|---|---|
| Male | 132 (41.6%) | 52 (37.4%) | 54 (42.9%) | 26 (50%) | >0.05 |
| Age | 57.67 ± 11.42 | 54.98 ± 10.46 | 58.52 ± 11.80 | 62.81 ± 11.07 | <0.01 |
| Height, cm | 162.29 ± 7.53 | 162.12 ± 7.05 | 162.37 ± 7.54 | 162.56 ± 8.82 | >0.05 |
| Weight, kg | 60.36 ± 10.51 | 61.00 ± 10.79 | 59.90 ± 9.56 | 59.75 ± 12.03 | >0.05 |
| BMI, kg/m2 | 22.82 ± 3.05 | 23.10 ± 3.04 | 22.65 ± 2.92 | 22.49 ± 3.38 | >0.05 |
| BSA, m2 | 1.69 ± 0.17 | 1.69 ± 0.17 | 1.68 ± 0.15 | 1.68 ± 0.19 | >0.05 |
|
| <0.01 | ||||
| I–II | 149 (47.0%) | 91 (65.5%) | 50 (39.7%) | 8 (15.4%) | |
| III | 136 (42.9%) | 41 (29.5%) | 68 (54.0%) | 27 (51.9%) | |
| IV | 32 (10.1%) | 7 (5.0%) | 8 (6.3%) | 17 (32.7%) | |
| NT-BNP | 292 (136–576) | 184.5 (118–328.25) | 305.0 (155.5–700) | 550.5 (302.25–921.75) | <0.01 |
| Total bilirubin | 14 (10–20) | 12 (8.75–16) | 14 (10–19) | 21.5 (12.75–30.25) | <0.01 |
| Creatinine | 73 (64–87) | 70 (61–82) | 73 (65–89) | 80.5 (71.5–101) | <0.01 |
| AF | 203 (64.0%) | 73 (52.5%) | 83 (65.9%) | 47 (90.4%) | <0.01 |
|
| |||||
| LVDd, mm | 50.87 ± 9.28 | 49.30 ± 9.15 | 52.07 ± 8.82 | 52.27 ± 10.28 | <0.05 |
| LVDs, mm | 33.79 ± 7.10 | 32.25 ± 6.31 | 35.19 ± 7.29 | 34.63 ± 8.01 | <0.05 |
| LA, mm | 50 (44–58) | 48 (43–56) | 51 (45–58) | 52 (48–59.5) | <0.05 |
| EF, % | 62 (58.5–67) | 63 (59–68) | 62 (56–66) | 62 (58–68.5) | >0.05 |
| FS, % | 34 (31–38) | 34 (32–38) | 33 (31–37) | 33 (30–38) | >0.05 |
| RA S-L, mm | 51.36 ± 11.94 | 45.03 ± 8.19 | 49.72 ± 10.11 | 59.81 ± 13.02 | <0.01 |
| RA S-I, mm | 66.61 ± 13.70 | 60.95 ± 11.89 | 63.94 ± 11.59 | 76.16 ± 13.87 | <0.01 |
| TV S-L, mm | 38.02 ± 6.62 | 34.33 ± 5.25 | 37.92 ± 4.70 | 45.39 ± 7.51 | <0.01 |
| TV A-P, mm | 38.01 ± 6.04 | 35.96 ± 4.67 | 37.69 ± 4.69 | 42.88 ± 8.54 | <0.01 |
| RVd mid, mm | 33.32 ± 10.13 | 30.89 ± 4.11 | 31.90 ± 4.68 | 34.74 ± 5.82 | <0.05 |
| TAPSE, mm | 18.88 ± 4.58 | 22.42 ± 7.27 | 17.83 ± 3.12 | 18.44 ± 3.72 | <0.01 |
| PASP, mmHg | 50 (44–63) | 47 (41–55) | 54 (46–65) | 56 (46.5–65) | <0.01 |
|
| >0.05 | ||||
| Rheumatic | 206 (65.0%) | 93 (66.9%) | 78 (61.9%) | 35 (67.3%) | |
| Degenerative | 103 (32.5%) | 42 (30.2%) | 45 (35.7%) | 16 (30.8%) | |
| Endocarditis | 8 (2.5%) | 4 (2.9%) | 3 (2.4%) | 1 (1.9%) | |
|
| <0.01 | ||||
| Kay procedure | 13 (4.1%) | 6 (4.3%) | 7 (5.6%) | 0 | |
| Sorin Sovering | 258 (81.4%) | 120 (86.3%) | 101 (80.2%) | 37 (71.2%) | |
| Edwards MC3 | 46 (14.5%) | 13 (9.4%) | 18 (14.3%) | 15 (28.8%) | |
|
| |||||
| MVR | 167 | 63 | 61 | 33 | |
| AVR | 9 | 4 | 3 | 2 | |
| DVR | 107 | 47 | 45 | 15 | |
| MVP | 45 | 22 | 16 | 7 | |
| CABG | 4 | 0 | 1 | 1 | |
| COX-MAZE | 5 | 3 | 1 | 1 |
BMI, body mass index; BSA, body surface area; NYHA, New York Heart Association; NT-BNP, N-terminal pro-brain natriuretic peptide; AF, atrial fibrillation; LVDd, left ventricular dimension in diastole; LVDs, left ventricular dimension in systole; LA, left atrial dimension; EF, ejection fraction; FS, shortening fraction; RA S-L, septal-lateral diameter of right atrium in apical four-chamber view; RA S-I, supero-inferior diameter of right atrium in apical four-chamber view; TV S-L, septo-lateral diameter of tricuspid annulus; TV A-P, antero-posterior diameter of tricuspid annulus; RVd mid, middle right ventricular diameter in diastole; TAPSE, tricuspid annular plane systolic excursion; PASP, pulmonary artery systolic pressure; AF, atrial fibrillation; MVR, mitral valve replacement; MVP, mitral valve repair; AVR, aortic valve replacement; DVR, double valve replacement; CABG, coronary artery bypass grafting; ASD, atrial septal defect.
Comparison between group 1 and group 2 or group 3:
p < 0.05,
p < 0.01.
Comparison between group 2 and group 3:
p < 0.05,
p < 0.01.
Tricuspid annulus obtained by intraoperative measurement.
|
|
|
|
|
| |
|---|---|---|---|---|---|
| Anterior annulus, mm | 38.44 ± 8.02 | 36.71 ± 6.30 | 38.21 ± 8.35 | 41.63 ± 9.20 | <0.01 |
| Posterior annulus, mm | 35.13 ± 7.76 | 33.31 ± 6.94 | 35.56 ± 7.63 | 38.98 ± 8.70 | <0.01 |
| Septal annulus, mm | 40.04 ± 6.62 | 38.11 ± 5.28 | 39.76 ± 6.90 | 42.46 ± 7.50 | <0.01 |
| A+P, mm | 73.58 ± 13.09 | 70.02 ± 10.64 | 73.77 ± 13.14 | 80.61 ± 14.63 | <0.01 |
| Anterior index, mm/m2 | 23.05 ± 5.29 | 21.83 ± 3.96 | 22.82 ± 4.85 | 25.67 ± 7.35 | <0.01 |
| Posterior index, mm/m2 | 20.96 ± 4.76 | 19.81 ± 4.36 | 21.30 ± 4.54 | 23.28 ± 5.43 | <0.01 |
| Septal index, mm/m2 | 23.92 ± 4.36 | 22.72 ± 3.92 | 23.78 ± 4.07 | 25.49 ± 5.19 | <0.01 |
| Anterior annulus% | 33.77 ± 4.12 | 33.92 ± 4.02 | 33.66 ± 4.26 | 33.83 ± 4.00 | >0.05 |
| Posterior annulus% | 30.83 ± 4.47 | 30.68 ± 4.44 | 31.32 ± 4.33 | 31.67 ± 4.95 | >0.05 |
| Septal annulus% | 35.40 ± 4.22 | 35.40 ± 4.15 | 35.02 ± 4.13 | 34.50 ± 4.62 | >0.05 |
| A+P% | 64.60 ± 4.22 | 64.60 ± 4.15 | 64.98 ± 4.13 | 66.04 ± 4.62 | >0.05 |
| TAC, mm | 113.62 ± 16.91 | 108.13 ± 13.02 | 113.53 ± 17.40 | 123.07 ± 18.11 | <0.01 |
| TACI, mm/m2 | 67.80 ± 11.07 | 64.35 ± 9.33 | 67.90 ± 10.20 | 74.45 ± 13.26 | <0.01 |
A+P, the length of anterior plus posterior annulus; Anterior/ Posterior/ Septal index, anterior/ posterior/ septal annulus divided by body surface area; Anterior/ Posterior/ Septal annulus%, the ratio of anterior/ posterior/ septal annulus to the tricuspid annulus circumference; A+P%, the ratio of anterior plus posterior annulus to the tricuspid annulus circumference; TAC, tricuspid annulus circumference; TACI, tricuspid annulus circumference index (circumference/ body surface area). Comparison between group 1 and group 2 or group 3:
p < 0.05,
p < 0.01 Comparison between group 2 and group 3:
p < 0.05,
p < 0.01.
Figure 1The length of each segment of tricuspid annulus (TA) was measured intraoperatively. Each segment of TA [(A) anterior annulus; (B) posterior annulus; (C) septal annulus] was compared between three groups [group 1 (G1), group 2 (G2), and group 3 (G3)]. The percentage of dilation of each segment of TA was illustrated. *p < 0.05, **p < 0.01.
Univariate and multivariate analysis of risk factors of severe FTR.
|
|
| |||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
|
| ||||||
| Age, per year | 0.052 | (1.023–1.085) | <0.01 | |||
|
| ||||||
| III | 1.474 | (1.908–9.988) | <0.01 | 1.108 | (1.201–7.629) | <0.05 |
| IV | 2.994 | (7.387–54.012) | <0.01 | 2.242 | (2.820–31.404) | <0.05 |
| NT-BNP, per 100 pg/mL | 0.036 | (1.000–1.001) | 0.068 | |||
| TB, per μmol/L | 0.120 | (1.081–1.175) | <0.01 | |||
| Cr, per μmol/L | 0.012 | (1.004–1.021) | <0.01 | |||
| Preoperative AF | 1.882 | (2.530–17.049) | <0.01 | 1.795 | (1.889–19.170) | <0.01 |
| LA, per mm | 0.038 | (1.013–1.065) | <0.01 | |||
| RA S-L, per mm | 0.094 | (1.056–1.144) | <0.01 | |||
| RA S-I, per mm | 0.090 | (1.055–1.134) | <0.01 | |||
| TV A-P, per mm | 0.185 | (1.091–1.326) | <0.01 | |||
| TV S-L, per mm | 0.253 | (1.166–1.422) | <0.01 | |||
| PASP, per mmHg | 0.18 | (0.998–1.038) | 0.084 | |||
| Anterior annulus, per mm | 0.086 | (1.051–1.129) | <0.01 | |||
| Anterior index, per mm/m2 | 0.144 | (1.092–1.220) | <0.01 | |||
| Posterior annulus, per mm | 0.076 | (1.037–1.123) | <0.01 | |||
| Posterior index, per mm/m2 | 0.120 | (1.057–1.204) | <0.01 | |||
| Septal annulus, per mm | 0.092 | (1.047–1.147) | <0.01 | |||
| Septal index, per mm/m2 | 0.135 | (1.066–1.229) | <0.01 | |||
| TAC, per mm | 0.052 | (1.034–1.073) | <0.01 | |||
| TACI, per mm/m2 | 0.075 | (1.047–1.109) | <0.01 | 0.062 | (1.027–1.103) | <0.01 |
| Rheumatic valve disease | 0.498 | (0.986–2.990) | 0.089 | |||
| Mitral stenosis | 0.986 | (1.404–5.128) | <0.01 | 1.153 | (1.379–7.299) | <0.01 |
| Mitral regurgitation | 0.640 | (1.036–3.472) | <0.05 | |||
|
| ||||||
| Age, per year | 0.060 | (1.024–1.102) | <0.01 | |||
| BSA, per m2 | −2.709 | (0.005–0.959) | <0.05 | |||
| Preoperative FTR | <0.01 | |||||
| Moderate FTR | 1.543 | (1.304–16.768) | <0.05 | |||
| Severe FTR | 2.463 | (3.336–41.275) | <0.01 | 2.548 | (1.961–45.955) | <0.05 |
| Postoperative AF | 1.026 | (1.055–7.372) | <0.05 | |||
| TV S-L, per mm | 0.046 | (0.988–1.110) | 0.081 | |||
| RA S-I, per mm | 0.038 | (1.009–1.069) | <0.05 | |||
| RA S-L, per mm | 0.035 | (1.005–1.067) | <0.05 | |||
| Anterior annulus, per mm | 0.039 | (1.000–1.080) | 0.050 | |||
| Anterior index, per mm/m2 | 0.078 | (1.028–1.138) | <0.01 | |||
| Posterior index, per mm/m2 | 0.078 | (1.005–1.163) | <0.05 | |||
| Septal annulus, per mm | 0.047 | (0.997–1.109) | 0.092 | |||
| Septal index, per mm/m2 | 0.091 | (1.013–1.183) | <0.05 | |||
| TAC, per mm | 0.023 | (1.003–1.045) | <0.05 | |||
| TACI, per mm/m2 | 0.044 | (1.014–1.077) | <0.01 | 0.044 | (1.014–1.077) | <0.01 |
| Rheumatic valve disease | 0.332 | (0.973–2.038) | 0.087 | |||
NYHA, New York Heart Association; NT-BNP, N-terminal pro-brain natriuretic peptide; TB, total bilirubin; Cr, creatinine; AF, atrial fibrillation; LVDd, left ventricular dimension in diastole; LVDs, left ventricular dimension in systole; LA, left atrial dimension; EF, ejection fraction; RA S-L, septal-lateral diameter of right atrium in apical four-chamber view; RA S-I, supero-inferior diameter of right atrium in apical four-chamber view; TV S-L, septo-lateral diameter of tricuspid annulus; TV A-P, antero-posterior diameter of tricuspid annulus; RVd mid, middle right ventricular diameter in diastole; TAPSE, tricuspid annular plane systolic excursion; PASP, pulmonary artery systolic pressure; Anterior/ Posterior/ Septal index, anterior/ posterior/septal annulus divided by body surface area; TAC, tricuspid annulus circumference; TACI, tricuspid annulus circumference index (circumference/ body surface area).
Figure 2Receiver-operator characteristic curve showing the tricuspid annulus circumference index (TACI) (red line) and combined multivariate analysis model (blue line) including the TACI, NYHA classification, preoperative atrial fibrillation (AF), and preoperative mitral stenosis (MS) as the independent predictors of preoperative severe functional tricuspid regurgitation (FTR).
Figure 3Freedom from postoperative functional tricuspid regurgitation (FTR) recurrence according to the length of each segment of tricuspid annulus. Patients were grouped into tertiles (T1 shortest length and T3 longest length). (A) Patients were trisected based on the length of anterior annulus. (B) Patients were trisected based on the length of posterior annulus. (C) Patients were trisected grouped based on the length of septal annulus.